Thursday, 26 September 2013

Does Conatus Pharmaceuticals Have A Winner With Emricasan?



In the human body, 50 billion to 70 billion cells die every day to make room for an equivalent number of new cells that are produced through cell division. Every year, the human body produces and kills a mass of cells equal to its entire body weight.

Scientists are studying apopsotis, a sort of "suicide mechanism" that instructs cells when it is time to die. Researchers are finding that a growing number of diseases occur when the regulation of this cell suicide program is defective.

San Diego-based Conatus Pharmaceuticals (CNAT) is at the forefront of studying the role of apoptosis in liver disease, the 150M market cap biotechnology company is focused on the development of emricasan. Read more


 


No comments:

Post a Comment